No results for ‘’
Lyka Labs Ltd
₹67.38
(3.83%)
Tue, 23 Jun 2026, 04:28 am
Health Technology
Pharmaceuticals: Other
24.5KLyka Labs PE Ratio
| Particulars | 2005 | 2006 | 2007 | 2009 | 2010 | 2011 | 2012 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 15.43 | 0 | 29.30 | 0 | 0 | 0 | 47.67 | 0 | 0 | 0 | 0 | 0 | 9.98 | 0 | 0 | 44.83 |
| Price to book ratio | 2.16 | 1.11 | 1.03 | 0.84 | 0.67 | 0.33 | 0.30 | 0.77 | 4.05 | 3.19 | 2.61 | 1.60 | 0 | 0 | 29.17 | 7.07 | 5.14 | 3.48 |
| Price to sales ratio | 1.24 | 0.58 | 0.72 | 0.49 | 0.49 | 0.22 | 0.16 | 0.44 | 1.35 | 1.12 | 2.02 | 1.02 | 0.60 | 0.88 | 2.02 | 3.29 | 3.18 | 2.61 |
| Price to cash flow ratio | 2.75 | 0 | 0 | 0 | 0 | 0 | 0 | 0.58 | 0 | 8.99 | 67.68 | 3.51 | 0 | 24.60 | 6.75 | 0 | 0 | 0 |
| Enterprise value | 116Cr | 83.58Cr | 117Cr | 154Cr | 180Cr | 151Cr | 169Cr | 190Cr | 283Cr | 248Cr | 232Cr | 166Cr | 168Cr | 231Cr | 503Cr | 365Cr | 402Cr | 397Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 15.83 | 18.82 | 9.66 | 23.89 | 12.76 | 135.51 | 16.03 | 12.13 | 0 | 0 | 0 | 12.74 | 5.23 | 23.16 | 28.14 | 23.46 |
| Debt to equity ratio | 2.23 | 1.27 | 0.70 | 1.27 | 1.12 | 1.74 | 2.30 | 3.08 | 2.57 | 3.33 | 2.28 | 2.24 | 0 | 0 | 9.78 | 1.65 | 0.86 | 0.38 |
| Return on equity % | 0 | -30.25 | 6.75 | 0 | 2.61 | -0.55 | -1.02 | 0 | 7.75 | -13.87 | -39.63 | -12 | -423.07 | 0 | 0 | -44.95 | -4.38 | 9.33 |
Lyka Labs Ltd Price to Earnings Ratio
The Lyka Labs Ltd Price to Earnings Ratio is a key financial metric used by investors to evaluate Lyka Labs Ltd's valuation, profitability, and overall financial performance. Tracking the Lyka Labs Ltd Price to Earnings Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Lyka Labs Ltd (NSE: LYKALABS, BSE: 500259) is currently trading at ₹67.38, with a market capitalization of ₹242.37Cr. As a leading company in the Health technology sector and Pharmaceuticals: other industry, monitoring the Lyka Labs Ltd Price to Earnings Ratio is essential for fundamental analysis.
Lyka Labs Ltd Price to Earnings Ratio Current Value
The current Lyka Labs Ltd Price to Earnings Ratio stands at 44.83.
The latest Lyka Labs Ltd Price to Earnings Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Lyka Labs Ltd Price to Earnings Ratio Historical Trend
The Lyka Labs Ltd Price to Earnings Ratio has shown the following historical trend:
- 2024: 44.83
- 2023: 0
- 2022: 0
- 2021: 9.98
- 2020: 0
The recent rise in Lyka Labs Ltd Price to Earnings Ratio suggests strengthening valuation trends and improving market sentiment.
What Lyka Labs Ltd Price to Earnings Ratio Indicates for Investors
The Lyka Labs Ltd Price to Earnings Ratio plays a crucial role in understanding the company's financial health and valuation.
A higher P/E ratio indicates investors expect strong future earnings growth, while a lower ratio may signal undervaluation.
Lyka Labs Ltd Price to Earnings Ratio Analysis Summary
The Lyka Labs Ltd Price to Earnings Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Lyka Labs Ltd Price to Earnings Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Lyka Labs Ltd Price to Earnings Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.